Advances in MRD Testing for Informed CRC Treatment - Episode 1

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

, , ,

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Now Viewing
EP. 1: Treating Colorectal Cancer: Overview of MRD Testing and ctDNA
EP. 2: When is MRD Testing Performed in Colorectal Cancer Treatment?
EP. 3: MRD Testing Platforms in Colorectal Cancer
EP. 4: Testing for MRD in Colorectal Cancer
EP. 5: Colorectal Cancer: MRD Testing in the Community Setting
EP. 6: Practical Considerations in MRD Testing in CRC
EP. 7: Evolution of MRD Testing in Colorectal Cancer
EP. 8: Patient Profile: A 52-Year-Old Woman With Colorectal Cancer
EP. 9: Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan
EP. 10: BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer
EP. 11: Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD
EP. 12: Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer
EP. 13: Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer
EP. 14: Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2
EP. 15: CIRCULATE-NORTH AMERICA and Barriers to Enrollment
EP. 16: MRD Testing in CRC: Gaps in our Understanding and Potential Advancements
EP. 17: Trajectory of CRC Treatment Landscape

Related Content:

Advances in MRD Testing for Informed CRC TreatmentGeorgetown Lombardi Comprehensive Cancer CenterFred Hutch Cancer CenterWeill Cornell Medical College Sandra & Edward Meyer Cancer CenterOncLive Peer Exchange® Colorectal Cancer
Clinical Considerations for 2L Treatment Sequencing in mCRC
Overview of Molecular Testing and Barriers in mCRC
ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC